| Symbol | ARTV |
|---|---|
| Name | ARTIVA BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5505 MOREHOUSE DRIVE,DRIVE, SAN DIEGO, California, 92121, United States |
| Telephone | (858) 267-4467 |
| Fax | — |
| — | |
| Website | https://www.artivabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001817241 |
| Description | Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Additional info from NASDAQ: |
RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 264.6K shares of Artiva Biotherapeutics, Inc. (ARTV) at $9.96 ($2.6M) Transaction Date: Jul 21, 2026 | Filing ID: 000791
Read moreNew Form SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001346824-26-000203 <b>Size:</b> 18 KB
Read moreNew Form 4/A - Artiva Biotherapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001231919-26-000790 <b>Size:</b> 15 KB
Read more(99% Neutral) ARTIVA BIOTHERAPEUTICS, INC. (ARTV) Announces Update on Collaboration with Common Stock
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 160.4K shares of Artiva Biotherapeutics, Inc. (ARTV) at $8.95 ($1.4M) Transaction Date: Jul 16, 2026 | Filing ID: 000774
Read moreArtiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 32.9K shares of Artiva Biotherapeutics, Inc. (ARTV) at $8.98 Transaction Date: Jun 25, 2026 | Filing ID: 000711
Read moreArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 531.3K shares of Artiva Biotherapeutics, Inc. (ARTV) at $8.99 ($4.6M) Transaction Date: Jun 12, 2026 | Filing ID: 000656
Read moreNew Form SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0001346824-26-000173 <b>Size:</b> 17 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell The… | Phase2 | Refractory Rheumatoid Arthritis (RA) | Recruiting | 2025-07-09 | 2029-01-01 | ClinicalTrials.gov |
| NCT06699771 | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Pat… | Phase1 | Lymphoma, T-Cell | Recruiting | 2025-03-07 | 2027-08-01 | ClinicalTrials.gov |
| NCT06581562 | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining… | Phase1 | Rheumatoid Arthritis | Recruiting | 2024-05-15 | 2028-12-01 | ClinicalTrials.gov |
| NCT06265220 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatmen… | Phase1 | Lupus Nephritis - WHO Class III | Active_Not_Recruiting | 2024-04-03 | 2027-08-01 | ClinicalTrials.gov |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and C… | Phase2 | Relapsed or Refractory Hodgkin Lymphoma | Terminated | 2023-10-10 | 2025-06-13 | ClinicalTrials.gov |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects Wi… | Phase1 | Breast Cancer | Withdrawn | 2023-08-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT04673617 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refracto… | Phase1 | Non Hodgkin Lymphoma | Completed | 2021-03-29 | 2025-10-06 | ClinicalTrials.gov |
| NCT03247439 | Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint… | Na | Osteoarthritis | Unknown | 2017-12-22 | 2024-03-01 | ClinicalTrials.gov |
| NCT02978573 | Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant… | Phase3 | Osteoarthritis of First Metatarsalphalangeal Joint | Completed | 2016-10-01 | 2018-04-27 | ClinicalTrials.gov |
| NCT02452671 | Observational Plan to Obtain Clinical Experience and Follow up Data on the Use … | — | Toe Joint Deformity | Terminated | 2015-06-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT00969969 | A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment… | Phase3 | Osteoarthritis of First Metatarsalphalangeal Joint | Completed | 2009-08-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00642382 | Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis | Na | OSTEOARTHRITIS | Terminated | 2008-04-01 | 2008-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Fludarabine | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| GCC2005 | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Cartiva | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT00969969 |
| Arthrodesis | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT00969969 |
| Cartiva | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT00969969 |
| Arthrodesis | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT00969969 |
| Normal saline | Other | Approved | OSTEOARTHRITIS | TERMINATED | NCT00642382 |
| Agilus | Other | Approved | OSTEOARTHRITIS | TERMINATED | NCT00642382 |
| Normal saline | Other | Approved | OSTEOARTHRITIS | TERMINATED | NCT00642382 |
| Agilus | Other | Approved | OSTEOARTHRITIS | TERMINATED | NCT00642382 |
| Cartiva | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT02978573 |
| Cartiva | Other | Phase PHASE3 | Osteoarthritis of First Metatarsalphalangeal Joint | COMPLETED | NCT02978573 |
| Cartiva | Other | Approved | Osteoarthritis | UNKNOWN | NCT03247439 |
| Cartiva | Other | Approved | Osteoarthritis | UNKNOWN | NCT03247439 |
| Cartiva | Other | Approved | Osteoarthritis | UNKNOWN | NCT03247439 |
| Fludarabine | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |
| Cyclophosphamide | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |
| Rituximab | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |
| AB-101 | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |
| Fludarabine | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| GCC2005 | Other | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Fludarabine | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT05678205 |
| Cyclophosphamide | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT05678205 |
| AB-201 | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT05678205 |
| Interleukin-2 | Other | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| Fludarabine | Other | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| Cyclophosphamide | Other | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| AB-101 | Other | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| AFM13 | Other | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| Obinutuzumab | Other | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| Rituximab | Other | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| Fludarabine | Other | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| AB-101 | Other | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| Allogeneic NK Cells | Other | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| Bendamustine | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Fludarabine | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Cyclophosphamide | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Interleukin-2 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Rituximab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| AB-101 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Allogeneic NK Cells | DRUG | Phase PHASE2 | Refractory Rheumatoid Arthritis (RA) | RECRUITING | NCT06991114 |
| GCC2005 | DRUG | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Obinutuzumab | DRUG | Phase PHASE1 | Lupus Nephritis - WHO Class III | ACTIVE_NOT_RECRUITING | NCT06265220 |
| AFM13 | DRUG | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| AB-201 | DRUG | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT05678205 |
| Bendamustine | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT04673617 |
| Fludarabine | DRUG | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Lymphoma, T-Cell | RECRUITING | NCT06699771 |
| Interleukin-2 | DRUG | Phase PHASE2 | Relapsed or Refractory Hodgkin Lymphoma | TERMINATED | NCT05883449 |
| Rituximab | DRUG | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |
| AB-101 | DRUG | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06581562 |